Table 1 (abstract P13). See text for description
From: Proceedings of the 9th International Symposium on MDS and SAA in Childhood
| Â | Karyotype | Mutated gene | Therapeutic approach |
|---|---|---|---|
Patient-1 | 45,XY,-7[8]/46,XY[2] | KRAS (somatic) | Cytoreduction (6-MP/AraC) + SCT |
Patient-2 | 46,ΧΧ[25] | NRAS (germline) | 6-MP (for 3 years) then watchful waiting |
Patient-3 | 47,XYY,1qh+[25] | CBL (germline) | Watchful waiting |
Patient-4 | 46,ΧΥ[25] | KRAS (somatic) | Azacitidine+SCT, Azacitidine+venetoclax+2nd SCT |
Patient-5 | 46,ΧΥ[25] | RRAS2 (germline) | Watchful waiting |
Patient-6 | 46,ΧΧ[19] | PTPN11 (somatic) | Azacitidine+SCT |